Financial Statements — BMR
Balance Sheet
(in millions USD)| Metric | Q2
2025 | Q2
2024 | Q2
2023 |
|---|
| Cash & Equivalents | 6.29 | 14.16 | 6.22 |
| Short-term Investments | 7.60 | 3.50 | -- |
| Accounts Receivable | 0.22 | 0.13 | 0.41 |
| Total Current Assets | 14.54 | 18.16 | 6.88 |
| Property, Plant & Equipment | 0.04 | 0.03 | 0.02 |
| Goodwill | 4.38 | 4.38 | 4.38 |
| Intangible Assets | 0.38 | 0.60 | 0.06 |
| Total Non-current Assets | 4.80 | 5.01 | 4.45 |
| Total Assets | 19.34 | 23.17 | 11.33 |
| Accounts Payable | 0.01 | 0.01 | 0.02 |
| Short-term Debt | -- | -- | 0.33 |
| Total Current Liabilities | 1.05 | 0.94 | 0.99 |
| Long-term Debt | -- | -- | 0.28 |
| Total Non-current Liabilities | 0.05 | 0.08 | 0.38 |
| Total Liabilities* | 1.10 | 1.03 | 1.36 |
| Retained Earnings | (38.21) | (33.64) | (31.90) |
| Total Stockholder Equity | 18.24 | 22.15 | 9.97 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2025 | Q2
2024 | Q2
2023 |
|---|
| Total Revenue | 1.07 | 1.00 | 0.96 |
| Cost of Revenue | 0.15 | 0.09 | 0.05 |
| Gross Profit | 0.92 | 0.92 | 0.91 |
| Research & Development | 2.04 | 1.00 | 0.91 |
| Selling, General & Admin | 1.23 | 1.15 | 0.80 |
| Total Operating Expenses | 4.34 | 2.46 | 1.91 |
| Operating Income | (3.42) | (1.55) | (1.00) |
| Pretax Income | (3.17) | (1.94) | (0.92) |
| Tax Provision | 0.01 | 0.02 | 0.01 |
| Net Income | (3.18) | (1.96) | (0.92) |
| Basic EPS | (0.21) | (0.13) | (0.10) |
| Diluted EPS | (0.21) | (0.13) | (0.12) |
Cash Flow Statement
(in millions USD)| Metric | Q2
2025 | Q2
2024 | Q2
2023 |
|---|
| Operating Cash Flow | (2.47) | (0.96) | (1.01) |
| Capital Expenditures | 0.01 | 0.02 | 0.00 |
| Free Cash Flow* | (2.48) | (0.97) | (1.02) |
| Investing Cash Flow | (7.61) | (3.81) | -0.00 |
| Financing Cash Flow | (0.11) | 12.81 | 6.55 |
* Derived from reported values
